Business Context and Reporting Period
Company: Silexion Therapeutics Corp (SLXN)
Filing Type: Form 8-K (Current Report)
Date of Report: July 29, 2026
Reporting Period: Single event date (July 29, 2026)
Business Context: The registrant is an emerging growth company incorporated in the Cayman Islands with principal executive offices in Ramat-Gan, Israel. The filing discloses a material clinical development milestone regarding its lead candidate, SIL204.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report focused on a specific corporate event and does not contain audited or unaudited financial statements.
Material Changes
Clinical Trial Initiation: On July 29, 2026, Silexion Therapeutics successfully initiated a Phase 2/3 clinical trial of its investigational drug, SIL204.
Indication: The trial targets patients with locally advanced pancreatic cancer.
Location: The trial is being conducted at the Tel Aviv Sourasky Medical Center.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the trial initiation. No specific financial guidance or quantitative outlook is provided in the text of this report.
Risks and Contingencies: The filing explicitly states that the information contained in Item 7.01 and the associated press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. Furthermore, this information is not incorporated by reference into filings under the Securities Act of 1933.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed trial design, patient enrollment targets, and primary endpoints.
- Confirm the regulatory status of the Phase 2/3 trial with the relevant health authorities (e.g., FDA, EMA, or Israeli Ministry of Health).
- Review the company's most recent 10-K or 10-Q filings to assess current cash runway and capital requirements to support the new trial.
- Monitor subsequent filings for updates on patient enrollment rates and any potential safety signals.